Every intervention Outliyr has scored for chronic pain, ranked by its BioHarmony score for this use case rather than its overall rating. The number beside each name is how well that one thing works for chronic pain; the tier beside it is what it is worth once safety, cost and effort are counted across everything else.
51 of 114 evaluated interventions score 3.0+ out of 10 for chronic pain · 5 comparisons
Oosterveld 2009 supports direction more than certainty. The existing rationale points to this narrower claim: this verified source studied infrared sauna in rheumatoid arthritis and ankylosing spondylitis and found short-term improvement in…
Whole-Body Vibration appears to modulate spinal muscle activation and improve proprioceptive feedback, mechanisms that can alleviate non-specific low back discomfort. The evidence tier for this indication is moderate, because most trials are…
Fan 2024 supports osteoarthritis pain reduction across RCTs, even with certainty limits. Red Light Therapy is most convincing for chronic joint, tendon, and inflammatory pain where the target is reachable. The effect…
OA, lumbar, and chronic musculoskeletal pain show consistent but heterogeneous benefit. Cochrane 2013 concluded electromagnetic fields probably relieve osteoarthritis pain, while Kull 2025 found randomized evidence generally favoring non-specific low-back pain outcomes…
Earthing as a grounding intervention shows modest analgesic signals in early surgical contexts, but larger independent trials are still missing. Ghaly and Teplitz 2004 adds pilot-level subjective pain data, yet the study…
The evidence points to a plausible use case without proving a universal response. Zeng X et al. 2026 is the best anchor here because it reports 11 randomized trials and 1,511 participants…
Resistance training is a well-supported management tool for several chronic pain conditions, particularly low back pain, knee osteoarthritis, and other musculoskeletal complaints, by strengthening supporting musculature and improving function and confidence in…
Duff 2024 found chronic pain results favoring auricular VNS, while Paccione 2022 suggests breathing can rival device-based fibromyalgia protocols. The score stays bounded because Vagus Nerve Stimulation evidence for chronic pain can…
Chronic-pain benefit is indirect through tissue recovery and inflammation modulation. Chronic tendinopathy reports are common, but no human pain RCT exists for TB-500. Use the score as an injury-resolution signal rather than…
Chronic pain may respond through central pain modulation, sleep improvement, and autonomic downshifting. Evidence is not strong enough to replace physical rehabilitation, load management, or medical evaluation. The score stays moderate because…
Jamialahmadi 2024 reports 7 trials; reported reductions in total cholesterol, triglycerides, and LDL, with no significant HDL change. Ye 2026 points in the same direction, but route, dose, baseline status, and outcome…
Konrad 2025 supports a favorable chronic nonspecific low back pain signal, with pain and function improvements in pooled WB-EMS studies. Best fit is supervised low-frequency WB-EMS as an adjunct to back-care programming.…
Lima 2024 reports Verified audit Track 1 source; six clinical trials with positive diabetic-foot-ulcer signals and considerable risk-of-bias caveats. Chang 2024 points in the same direction, but route, dose, baseline status, and…
Most of curcumin's pain benefit rides on the osteoarthritis data, where a 2019 head-to-head RCT by Shep and colleagues found curcumin roughly matched diclofenac for knee pain over 28 days with better…
Fibromyalgia and CRPS evidence support the chronic pain use case more than generic wellness slugs. Efrati 2015 reports tender-point reduction and quality-of-life gains after forty hard-chamber sessions. Niezgoda 2025 reviews CRPS evidence…
VA studies show reduced perceived pain in veterans; mechanism via vagal anti-nociceptive pathways. The score stays bounded because HRV Biofeedback evidence for chronic pain can depend on breathing cadence, adherence, baseline HRV,…
Miller et al. 2021 supports selective use. BFR is used in chronic pain rehabilitation because low loads can preserve strength work when heavy loading is painful, but direct chronic-pain evidence is moderate.…
Lang 2024 gives the most relevant evidence anchor. The existing rationale points to this narrower claim: Moderate aerobic exercise can reduce chronic pain through central pain modulation, mood, sleep, and gradual confidence…
Soh 2024 anchors the most relevant signal. Glycine fits chronic pain because glycine participates in sleep signaling, glutathione, collagen, methylation, and nervous-system balance, depending on the endpoint. The score stays bounded because…
Vasireddi 2025 anchors the most relevant signal. BPC-157 fits chronic pain when the target is tissue repair, vascular recruitment, or inflammation control, but the case still rests mostly on preclinical models. The…
Chronic pain can improve indirectly when weight loss reduces joint load and inflammation. Obesity related osteoarthritis patterns benefit most. There is no tirzepatide chronic pain RCT as the main indication. Retatrutide TRIUMPH…
Bliddal 2024 supports knee osteoarthritis pain improvement in people with obesity, but Semaglutide is not a broad analgesic. Pain improves most when mechanical load and inflammation are part of the driver. That…
The systematic review by Hussain 2018 noted symptomatic benefit for rheumatological conditions and pain across several included studies, and heat is one of the oldest comfort measures for muscle and joint pain,…
The evidence points to a plausible use case without proving a universal response. Xie et al. 2025 is the best anchor here because it reports 41 randomized trials, 3,759 participants and chronic…
Shoskes 1999 randomized 30 men with chronic prostatitis or chronic pelvic pain syndrome to 500 mg quercetin twice daily for 1 month, with 67 percent responding versus 20 percent on placebo by…
The existing rationale points to this narrower claim: Anti-inflammatory mechanism is chronic-pain-adjacent, but there are no direct pain RCTs. That does not make Ca-AKG (Calcium Alpha-Ketoglutarate) a targeted chronic-pain treatment. The report's…
PEARL female pain improvement is interesting, but chronic-pain scoring should remain low-to-moderate until replicated.
No direct chronic-pain evidence was verified. Mobility and strength improvements may indirectly reduce some pain burden in frail users.
Joint pain reduction is the main pain endpoint. UC-II, eggshell membrane, and specific collagen peptide trials support modest joint-pain benefit, but general chronic pain outside joints is unsupported.
Metformin may indirectly reduce diabetes-related neuropathic risk through glycemic control, but B12 depletion can complicate neuropathy. Direct chronic-pain evidence remains weak.
Chronic pain may improve indirectly in insulin-resistant or higher-weight users through weight loss, glycemic stabilization, and lower inflammatory load. Evidence in fibromyalgia, migraine, and inflammatory pain remains early. Strict keto can also…
Chronic neuropathic pain has real but weaker support than the nerve-structure signal. The sarcoidosis pilot improved the Small Fiber Neuropathy Screening List score significantly versus placebo, per Heij 2012, and the type-2-diabetes…
Chronic-pain claims are still weak for consumer oral use. Wickramasinghe 2025 and Zhu 2025 focus on short postoperative windows, so fibromyalgia or chronic-pain extrapolation remains mostly anecdotal.
The highest-certainty cannabinoid pain reviews are equivocal. A PRISMA systematic review of 12 human CBD pain studies per Villanueva 2022 concluded the evidence remains insufficient and mixed, with several studies showing no…
Chronic pain is the core approved use, and it is also where the evidence splits. For interstitial cystitis bladder pain a pooled meta-analysis of six placebo-controlled trials found modest but real improvement…
Chronic-pain stays at 4 because anti-inflammatory and anti-fibrotic mechanisms could matter in painful tissue remodeling, but human pain trials are not confirmed. He 2024 supports fibrosis biology, not analgesia.
Chronic pain has no Tβ4-specific human RCT. The case rests on the secondary effects of better tissue repair and inflammation control, which are indirect rather than analgesic mechanisms; for nerve pain specifically…
Chronic pain and hypogonadism can overlap, especially with opioids or frailty, but TRT is not first-line pain care. Consider it only when low testosterone is clearly documented and symptoms fit.
Pain benefit is likely indirect through weight loss and reduced joint load. Knee osteoarthritis is the most relevant signal, but retatrutide is not a general analgesic and chronic pain endpoints remain narrow.
Aerobic exercise can help chronic-pain management, but HIIT tolerability varies. Bike or pool alternatives may be better entry points than treadmill intervals.
May help inflammatory background load, but chronic pain requires domain-specific treatment and evidence is indirect.
Mixed. Graded aerobic activity can help some chronic pain, but adding spinal and joint load is the wrong direction for many low-back and knee pain patterns; individualize with a clinician.
Chronic-pain support is limited to dysmenorrhea and symptom-overlap contexts rather than broad pain syndromes; saffron is not a primary analgesic intervention.
Chronic-pain support is modest. Anti-inflammatory pathways and v0 joint-pain data justify the score, but ashwagandha is not an analgesic and lacks broad pain-condition RCT depth. Consider it adjunctive only when stress or…
Indirect via osteoarthritis joint comfort per de Carvalho 2024; not a general analgesic and weak outside joint pain.
Aerobic exercise can help chronic-pain management, but maximal sprint tolerability varies; lower-intensity entry points are usually better starts.
Anti-inflammatory and bone-joint signals may matter for some chronic pain contexts, but direct chronic-pain RCTs are absent.
Cortisol and stress modulation are chronic-pain-adjacent, but no direct pain RCT supports a therapeutic claim.
Pain meta-analysis is animal-only; no human pain-outcome trials for fucoidan.
Weight loss reduces load-related joint pain and there is early interest in GLP-1 effects on inflammatory and neuropathic pain, but the pain benefit is currently secondary to the weight change rather than…
No trial has tested pain scales, inflammatory pain, neuropathy, osteoarthritis, or analgesic use. Anecdotal pain relief appears intermittently in forums but is not systematic. The antioxidant rationale is indirect, and Kato 2010…
Nothing matches those filters.
Monthly out-of-pocket cost at the most accessible legitimate channel, at the dose the score was given for. 22 of 51 are not priced yet; those cells are left blank rather than guessed.
| Intervention | Monthly cost | At dose | How you get it |
|---|---|---|---|
| Infrared Sauna | $36–$73 | 55-60 degrees C, 20-30 min | Over the counter |
| Whole-Body Vibration | $50–$100 | 30 Hz, roughly 0.3g, 10-20 min standing | Over the counter |
| Red Light Therapy | $17–$43 | 10-20 min at 6-12 inches, full chest/face/back rotation | Over the counter |
| PEMF (Pulsed Electromagnetic Field Therapy) | $3–$117 | 20-30 min mat session | Over the counter |
| Earthing | Not priced yet | Over the counter | |
| Celebrex (Celecoxib) | Not priced yet | ||
| Strength / Resistance Training | $60 | 2 to 4 sessions/week | Over the counter |
| Vagus Nerve Stimulation | $4–$8 | 10-20 min auricular tVNS at comfortable perceptible intensity | Over the counter |
| TB-500 (Thymosin Beta-4 Fragment) | Not priced yet | ||
| Neurofeedback | Not priced yet | ||
| Molecular Hydrogen | Not priced yet | ||
| Full-Body EMS | Not priced yet | ||
| Ozone Therapy | $520–$2,600 | 20-30 mcg/mL ozone, roughly 1,000-1,500 mcg total per session | In clinic |
| Curcumin | $15–$40 | 500 mg curcuminoids | Over the counter |
| Hyperbaric Oxygen Therapy | $3,000–$6,000 | 2.0 ATA for 90 minutes with air breaks | In clinic |
| HRV Biofeedback | $5 | 20 min/session at individual RF (4.5 to 6.5 bpm) | Over the counter |
| Blood-Flow Restriction Training | Not priced yet | ||
| Zone 2 Cardio | Not priced yet | Over the counter | |
| Glycine | $2–$3 | 3 g oral glycine | Over the counter |
| BPC-157 | $40–$80 | 250 to 500 mcg SC 1 to 2x/day near injury site | Grey market |
| Tirzepatide | $299–$449 | 2.5 to 5 to 7.5 to 10 to 12.5 to 15 mg | Prescription |
| Semaglutide | $199–$349 | 0.25 mg weeks 1 to 4, 0.5 mg weeks 5 to 8, 1.0 mg weeks 9 to 12, 1.7 mg weeks 13 to 16, 2.4 mg week 17 onward | Prescription |
| Traditional Sauna (Finnish Dry-Heat) | $50 | 15 to 20 minutes at 80 to 100 C | Over the counter |
| Omega-3 | $20–$40 | 1-2 g/day combined EPA+DHA | Over the counter |
| Quercetin | $20–$50 | 200 mg/day | Over the counter |
| Ca-AKG (Calcium Alpha-Ketoglutarate) | $15–$30 | 1 g/day generic Ca-AKG oral | Over the counter |
| Rapamycin | $15–$50 | 3 mg | Prescription |
| Essential Amino Acids | Not priced yet | ||
| Collagen Peptides | $8–$40 | 2.5-10 g hydrolyzed collagen peptides | Over the counter |
| Metformin | $4–$30 | 500 mg with dinner for 1 week, then 500 mg twice daily for 1 week, then increase by 500 mg/week toward 1000 mg twice daily as tolerated | Prescription |
| Ketogenic Diet | $100 | Standard keto, 40-50 g total carbohydrate/day | Over the counter |
| ARA-290 (Cibinetide) | Not priced yet | ||
| Methylene Blue | $13–$40 | 0.5-5 mg oral | Over the counter |
| Full-Spectrum Hemp (CBD) | Not priced yet | ||
| Pentosan Polysulfate (Elmiron) | Not priced yet | ||
| GHK-Cu | $30–$100 | 0.5-3% topical serum or cream | Over the counter |
| Thymosin Beta-4 (Tβ4) | Not priced yet | ||
| TRT (Testosterone Replacement Therapy) | $50–$300 | Clinician-selected formulation at the lowest dose likely to restore physiologic testosterone | Prescription |
| Retatrutide | $130–$960 | 2 mg, then 4 mg, then 8 mg or 12 mg weekly depending on protocol and tolerability | Research use only |
| Norwegian 4×4 | Not priced yet | Over the counter | |
| Astaxanthin | Not priced yet | ||
| Rucking (Weighted Walking) | Not priced yet | ||
| Saffron | Not priced yet | ||
| Ashwagandha | $15–$30 | 300 mg KSM-66 with breakfast and 300 mg with dinner | Over the counter |
| Hyaluronic Acid | Not priced yet | ||
| Sprinting (Sprint Interval Training) | Not priced yet | ||
| Shilajit | $25–$50 | 500 mg purified shilajit | Over the counter |
| Tongkat Ali | $20–$40 | 200 mg/day Physta standardized extract | Over the counter |
| Fucoidan (Brown Seaweed Polysaccharide) | Not priced yet | ||
| GLP-1 Receptor Agonists | Not priced yet | ||
| C60 (Buckminsterfullerene) | Not priced yet |
Head-to-head reports and category rankings that name a winner on this use case.
Red light therapy leads recovery at 7.5–8.0/10, with infrared sauna close behind at 7.5–8.0/10. This page ranks by the recovery subrating, not the overall score, and that changes…
Buy the panel. Red light therapy scores 7.5–8.0/10 against HBOT's 5.5–6.0/10, costs $17 to $43 a month against $3,000 to $6,000, and does not lose a single use…
Red light therapy scores 7.5–8.0/10 and PEMF 7.5–8.0/10, so the panel is the better first buy for most people. PEMF wins on bone and joint pain, where a…
HBOT scores 5.5–6.0/10 and ozone 5.0–5.5/10, but ozone wins several use cases outright. Pick HBOT for wounds, cognition and neuro recovery, at $3,000 to $6,000 a month. Pick…
Red light therapy scores 7.5–8.0/10 and infrared sauna 7.0–7.5/10, so buy the panel first. It costs less, targets skin, hair, joints and recovery directly, and carries higher evidence…
Infrared Sauna, at 7.5–8.0 out of 10 for chronic pain. Oosterveld 2009 supports direction more than certainty.
Of the top-scoring options, Glycine is the least expensive at about $2 a month, scoring 5.5–6.0 out of 10 for chronic pain.
C60 (Buckminsterfullerene) scores 3.0–3.5 out of 10 for chronic pain but only 4.0–4.5 overall, landing in the caution tier once safety, side effects, cost and effort are counted.
51 of the 114 interventions evaluated for chronic pain score 3.0 out of 10 or better, which is the cut-off for appearing on this page.
